Fig. 6From: The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysisForest plots of the meta-analysis on the effects of antiangiogenic drugs on grade ≥ 3 adverse effects (AEs). The angiogenesis inhibitors group had a greater incidence of grade ≥ 3 AEs than the control groupBack to article page